Browse Category

Pharmaceutical Industry 10 December 2025 - 19 December 2025

Hims & Hers Health (NYSE:HIMS) rises as FDA BPC-157 decision turns market attention to revenue per subscriber
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1
19 December 2025
····
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK plc is ending 2025 with a busy headline tape—exactly the kind of environment where investors tend to re-check both the “story” and the spreadsheet. On Thursday, December 18, 2025, GSK published a fresh share buyback update, while markets continue to digest a string of regulatory milestones across respiratory, vaccines, and infectious diseases that could shape the company’s growth profile into 2026.
18 December 2025
··
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma
16 December 2025
···
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4
14 December 2025
··
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex in Alzheimer’s disease—an outcome that investors had been bracing for since last month’s negative “trend vote” from the EMA’s scientific committee. European Medicines Agency+1
12 December 2025
·
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s next move.
10 December 2025
····
1 … 5 6 7 8 9 10
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.